- Brief report
- Open Access
Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia
Harm Reduction Journalvolume 16, Article number: 51 (2019)
Safe consumption spaces (SCS) are indoor environments in which people can use drugs with trained personnel on site to provide overdose reversal and risk reduction services. SCS have been shown to reduce fatal overdoses, decrease public syringe disposal, and reduce public drug consumption. Existing SCS research in the USA has explored acceptability for the hypothetical use of SCS, but primarily among urban populations of people who inject drugs (PWID). Given the disproportionate impact of the opioid crisis in rural communities, this research examines hypothetical SCS acceptability among a rural sample of PWID in West Virginia.
Data were drawn from a 2018 cross-sectional survey of PWID (n = 373) who reported injection drug use in the previous 6 months and residence in Cabell County, West Virginia. Participants were asked about their hypothetical use of a SCS with responses dichotomized into two groups, likely and unlikely SCS users. Chi-square and t tests were conducted to identify differences between likely and unlikely SCS users across demographic, substance use, and health measures.
Survey participants were 59.5% male, 83.4% non-Hispanic White, and 79.1% reported likely hypothetical SCS use. Hypothetical SCS users were significantly (p < .05) more likely to have recently (past 6 months) injected cocaine (38.3% vs. 25.7%), speedball (41.0% vs. 24.3%), and to report preferring drugs containing fentanyl (32.5% vs. 20.3%). Additionally, likely SCS users were significantly more likely to have recently experienced an overdose (46.8% vs. 32.4%), witnessed an overdose (78.3% vs. 60.8%), and received naloxone (51.2% vs. 37.8%). Likely SCS users were less likely to have borrowed a syringe from a friend (34.6% vs. 48.7%).
Rural PWID engaging in high-risk behaviors perceive SCS as an acceptable harm reduction strategy. SCS may be a viable option to reduce overdose fatalities in rural communities.
In 2017, there were more than 70,000 overdose fatalities in the USA (21.7 deaths per 100,000 people) with the highest state overdose mortality rate in West Virginia (57.8 deaths per 100,000 people) . No area of West Virginia has been harder hit by the opioid crisis than Cabell County which has the highest overdose mortality rate in the state reporting 152 deaths in 2017 and accounted for more than 20% of overdose fatalities in the state . In addition to overdose, people who inject drugs (PWID) are also at increased risk for HIV, hepatitis C (HCV), and skin and soft tissue infections [3,4,5,6]. In the wake of the 2015 Scott County, Indiana HIV epidemic where 215 incident cases of HIV were linked to injection drug use , 220 counties were identified as vulnerable to similar HIV outbreaks . These counties were concentrated in the Appalachian region of the eastern US; for example, 28 of the 55 counties in West Virginia were identified as vulnerable. Risks for adverse health consequences associated with the modern opioid crisis are exacerbated by multiple structural vulnerabilities (e.g., homelessness, poverty, diminished access to HIV prevention services) that are highly prevalent among PWID populations, especially those residing in rural areas. Additionally, PWID that are structurally vulnerable may also engage in public drug use, which has been linked to several adverse outcomes, including overdose, syringe sharing, and discarded syringes [9,10,11,12,13,14]. As rural communities respond to the consequences of the opioid crisis, many have chosen to implement harm reduction programs to not only prevent overdose fatalities and infectious disease outbreaks, but also link PWID to drug treatment programs and other essential health and human services.
Safe consumption spaces (SCS), also known as overdose prevention sites, supervised injection facilities, and drug consumption spaces, are public health facilities where individuals can use drugs under the supervision of trained staff . SCS offer sterile injection supplies (e.g., syringes, tourniquets, cookers) and proper disposal containers for waste related to injection drug use. Additionally, many SCS also provide naloxone, drug counseling, referrals to medical care and addiction treatment, HIV and HCV testing, and other social services. There are over 90 of these sites operating across the globe. The first SCS to open in North America was Insite, in Vancouver, Canada, in 2003 . Research has shown that SCS reduce overdose fatalities, public injection, HIV transmission, and publicly discarded syringes and injection-related litter (e.g., cookers) while increasing enrollment in addiction treatment services [17,18,19,20,21,22,23,24]. For example, in a study examining the overdose mortality rates outside of an SCS in Vancouver in the 2 years after its opening, researchers identified a 35% decrease in overdose mortalities within approximately one third of a mile of the SCS compared to 9% during the same period in the rest of the city . Further, SCS have been shown to be a cost-effective public health strategy via reducing treatment costs associated with incident HIV/HCV infections, wound care, and overdose-related services [26, 27]. Research has also shown that SCS implementation does not increase crime and can lead to reductions in calls for emergency services [28, 29]. A research study in Sydney, Australia examined calls to emergency responders for overdose and found an 80% reduction in calls in the area immediately surrounding the SCS during operating hours and a 45% reduction in calls across the broader surrounding area .
A small number of research studies have examined hypothetical acceptability of SCS among PWID in the US [31,32,33,34]. These studies report between 63 and 92% of PWID indicated likely use of a SCS if one existed in their community. Intent to use a hypothetical SCS was found to be most acceptable among those individuals reporting high-risk drug use behaviors (e.g., having recently used fentanyl or experienced an overdose), those engaging in public drug use, and those reporting being homeless. Current published studies were all conducted in urban settings; less is known about hypothetical SCS acceptability among PWID in rural areas. Given the disproportionate impact of the opioid crisis in rural communities, this research examines the hypothetical acceptability of SCS utilization among a rural sample of PWID in West Virginia.
This research is part of a larger study that aimed to estimate the number of PWID in Cabell County, WV; detailed methods describing data collection in the parent study can be found in related publications [35,36,37]. For brevity, we provide an overview. Surveys were conducted in June and July 2018 in Cabell County, West Virginia, during two separate, 2-week data collection periods as part of a capture-recapture population estimation study. Surveys were administered via audio computer-assisted self-interview (ACASI) at the Cabell-Huntington Health Department (CHHD) harm reduction program and in areas throughout the county where PWID frequent, such as local transportation hubs (i.e., bus stops), parks, and gas stations. The CHHD harm reduction program operates a single fixed site location which is open during normal health department operating hours and offers syringe exchange, naloxone, HIV and HCV testing, and referrals to drug treatment. Participants were verbally consented and received either a $10 grocery gift card or a small bag with food items as an incentive. In total, 373 individuals taking the survey indicated injection drug use in the past 6 months and residing in Cabell County, West Virginia. The institutional review board at the Johns Hopkins Bloomberg School of Public Health approved this research.
To assess hypothetical acceptability of SCS use, survey participants were first given a description of a SCS, “We want to ask you a question about a safe consumption space for drug use. A safe consumption space is a place where it would be legal for people to safely inject, snort, or smoke, or otherwise consume drugs that they buy somewhere else. You would not be arrested while in the site. There would be staff on site to respond to an overdose, and to provide basic medical care and referrals to health and social services upon request.” They were then asked, “How likely is it that you would use a safe consumption space?” with response options on a 4-point Likert scale from very likely to very unlikely. For these analyses, responses were dichotomized into “likely” (somewhat likely or very likely) and “unlikely” (somewhat unlikely or very unlikely) SCS users.
Socio-demographics included in these analyses were age, gender (male or female), race, ethnicity, sexual orientation, relationship status, education, homelessness, arrest, and current health insurance. Age was reported as a continuous measure. Due to a lack of diversity in responses related to race and ethnicity, these measures were collapsed to White, non-Hispanic versus all others. Relationship status was dichotomized to those currently married or with a partner vs. divorced or single. Education was dichotomized to those having graduated from high school or equivalent (GED) and those with education less than a high school diploma. Homelessness was assessed by participant yes/no responses to the question “Do you consider yourself homeless?”. Sexual minority status was defined as all individuals who identified as gay, lesbian, bisexual, or other orientation. Arrest was self-reported for any arrest in the previous 6 months.
Drug use measures included years of injection drug use, recent (past 6 months) drugs injected, and preference for drugs containing fentanyl. Years of injection drug use was calculated using reported age at time of survey administration and age at first injection drug use. Injected drug categories included cocaine, heroin, speedball (heroin and cocaine), crystal methamphetamine, fentanyl, buprenorphine or suboxone, and painkillers.
Injection drug use behaviors were measured by where they had recently (past 6 months) received sterile syringes, receptive injection equipment sharing, public drug consumption, overdose experiences, and naloxone access. Participants endorsed possible locations in which they had received sterile syringes in the past 6 months, including borrowed from a friend, a needle exchange program, and bought/received from another person. The number of recent (past 6 months) overdose experiences (fatal and nonfatal) witnessed were reported as continuous measures. For these analyses, responses were collapsed to a single variable indicating if a participant had witnessed at least one overdose (fatal or nonfatal) in the past 6 months. For having experienced a recent overdose, continuous responses were similarly dichotomized. Having recently (past 6 months) received naloxone was reported dichotomously (yes/no) via “…did you get Narcan or naloxone from any sources to prevent an overdose?.” Public drug consumption was dichotomized as those reporting typical recent (past 6 months) drug use location as in a home (their own or that of a friend) versus all other locations. Other locations included on the street, at a park, a stairwell in a building, abandoned building, public transit location (bus, train, etc.), a public bathroom, in the woods, and in a vehicle. Receptive injection equipment sharing was measured as reporting any use of syringes, cookers, cottons, or rinse water that the participant knew had been used by someone else during the previous 6 months.
Health-related measures included self-reported recent (past 6 months) HIV and HCV testing, wanting drug treatment, and comfort discussing drug use with doctors. For recent interest in wanting drug treatment, participants were asked “In the past 6 months, have you wanted to start drug treatment but not been able to get into a program?” and responded dichotomously (yes/no). Participants were asked how comfortable they would be talking to their doctor about their drug use and responded on a 4-point Likert scale from very comfortable to very uncomfortable. Responses were dichotomized to comfortable (very comfortable and somewhat comfortable) and uncomfortable (very uncomfortable and somewhat uncomfortable) talking about their drug use.
Differences between the likely and unlikely SCS group were analyzed across socio-demographics, drug use, injection drug use behaviors, and health-related measures using chi-square and t tests in SAS 9.4.
Nearly 80% (n = 295) of rural PWID reported very likely or likely use of a SCS. Table 1 summarizes the statistical findings.
Demographically, PWID were 35.8 years old (SD 8.6) and primarily male (59.5%), White, non-Hispanic (83.4%), and had at least a high school education (71.7%). Almost half were either married or in a relationship (47.3%). Socio-demographic measures of PWID showed 73.2% reported currently having health insurance, 57.1% reporting considering themselves homeless, and 30.6% reported having been recently arrested. No significant differences were found in socio-demographic measures between likely and unlikely SCS users.
The mean number of years of injection drug use averaged 10.9 (SD 9.2) years. The most commonly reported recently injected drugs were heroin (82.0%), crystal methamphetamine (71.0%), and fentanyl (56.3%). Likely SCS users reported significantly more recent injection use of speedball (cocaine and heroin) (41.0% vs. 24.3%, p = .0081) and cocaine (38.3% vs. 25.7%, p = .0427). Likely SCS users were significantly more likely to prefer drugs containing fentanyl than unlikely SCS users (32.5% vs. 20.3%, p = .0396).
When reporting places where PWID recently received new, sterile syringes, needle exchange programs were most commonly reported (66.0%) followed by borrowing from a friend (37.3%). Likely SCS users were significantly less likely to report having borrowed a syringe from a friend than unlikely SCS users (34.6% vs. 48.7%, p = .0253). Receptive injection equipment sharing (syringes, cookers, rinse water, or cotton) was reported by 60.3% and public drug use was reported by 48.6% of PWID.
Significant differences were found between likely and unlikely SCS users on measures of recent drug-related experiences. Significantly more likely SCS users reported recently experiencing an overdose (46.8% vs. 32.4%, p = .0262), witnessing a recent overdose (78.3% vs. 60.8%, p = .0019), and having recently received naloxone (51.2% vs. 37.8%, p = .0399).
In the area of health behaviors, likely SCS users reported being significantly more comfortable talking to doctors about their drug use than unlikely SCS users (71.0% vs. 55.4%, p = .0103). Additionally, though not significantly different from their unlikely SCS user counterparts, likely SCS users were more likely to report having recently (past 6 months) wanted drug treatment but not being able to get into a program (38.4% vs. 28.8%, p = .1246), received an HIV test (54.9% vs. 43.2%, p = .0722), and received a hepatitis C test (54.6% vs. 43.2%, p = .0809).
To our knowledge, this is the first study that has examined hypothetical SCS acceptability among a rural population of PWID, thus building on previous research in urban settings. In our study, PWID who reported likely SCS utilization reported being at significantly greater risk of overdose; for example, SCS users reported higher rates of recently witnessing an overdose, experiencing an overdose, injecting cocaine and speedball (cocaine and heroin), and preferring drugs containing fentanyl. Hypothetical SCS users were also more likely to already be engaging in harm reducing behaviors (e.g., HIV and HCV testing, less syringe borrowing) compared with their unlikely SCS utilizing counterparts. Lastly, likely SCS users reported significantly higher levels of comfort talking about their drug use with their doctors and wanting to get into drug treatment (but unable to get into a program). Our findings highlight that the portion of the PWID population that is more likely to use a hypothetical SCS reflects persons who would likely benefit the most from SCS utilization (i.e., those engaging in higher-risk injection drug use behaviors).
Our finding that nearly 80% of rural PWID reported likely hypothetical SCS utilization was similar to acceptability levels found in urban PWID populations in the USA (63 to 92%) [31,32,33,34]. Because data in our analyses were collected as part of a PWID population estimation involving the recruitment of individuals from a variety of locations in the community, findings are more likely to reflect the broader community-level acceptability of hypothetical SCS utilization among the PWID population in Cabell County. The high level of hypothetical SCS acceptability is also noteworthy given the stigmatization of addiction in rural communities. Unlike metropolitan areas, rural communities have experienced significant struggles to implement evidence-based opioid crisis response strategies (e.g., medication-assisted treatment, syringe services programs). Recent qualitative research indicates that rural PWID are regularly subjected to stigmatizing language, behaviors, and policies that impede their ability to engage in positive health-seeking behaviors . Given that SCS implementation in rural areas would require community support, future research should be conducted to understand overall community-level awareness of and acceptability for SCS implementation as well as where facilities could be implemented that best serve geographically dispersed PWID populations.
In comparison to related SCS acceptability research in the USA, we found both similarities and differences. Compared with urban-based SCS acceptability research, we did not find homelessness or public drug consumption to be related to likely SCS use, despite high levels of these indicators among our sample. Paralleling urban-based SCS acceptability research, we did, however, find that likely SCS users were more likely to report fentanyl preference and high rates of recent overdose experiences. Additionally, studies in urban settings have found that attendance at SCS has led to increased enrollment in drug treatment. Among our population who reported wanting drug treatment (but unable to get into a program), significantly more reported likely hypothetical SCS use, indicating that SCS implementation may be another avenue for connecting rural PWID to drug treatment programs. Given that our data are only able to speak to hypothetical SCS acceptability among a single rural PWID population, comparable research is needed in other non-urban areas to fully understand how urban and rural areas may differ in SCS acceptability.
Combining our hypothetical SCS acceptability data with related research allows us to estimate potential SCS utilization if a facility opened. In a study by DeBeck et al. , 72% of PWID who indicated willingness to use a SCS later accessed the SCS when it opened. Based on a recent study that estimated there were 1857 (95% CI 1147, 2657) PWID in Cabell County , we estimate that 1469 (95% CI 907, 2102) PWID would be open to using a SCS and 72% of that population (approximately 1058 [95% CI 653, 1513]) would potentially utilize the facility, if it existed. These data demonstrate that there is a large number of people in West Virginia that may potentially benefit from SCS implementation and that there is a need for additional research to understand how these programs could best serve rural PWID at high risk of HIV and overdose.
Cabell County has the highest drug overdose, fatal and nonfatal, rates in WV, and stakeholders throughout the community (e.g., first responders, Cabell-Huntington Health Department, local faith-based leaders, substance use treatment organizations) have joined forces to implement collaborative initiatives designed to improve the public health of PWID. These efforts have shown preliminary success; for example, compared to 2017, there was a 40% reduction in EMS calls for overdose in 2018 . Even with these measures, the overdose rate remains very high and continues to tax the community’s resources. One particularly high-risk period for overdose among PWID is in the time immediately following when persons are released from incarceration. Our findings indicate that close to one third of our participants reported having been recently arrested. Having an SCS may serve as a venue for PWID reentering the community to engage in harm reduction service provision and be connected to drug treatment programs as they reintegrate into society. SCS implementation may positively affect rural communities via reducing overdose fatalities, HIV incidence, and discarded syringes; however, additional research is warranted as SCS are both hypothetical interventions in the US and their implementation may differ between urban and rural contexts.
Our study had several limitations. First, because SCS implementation in a US context remains hypothetical, asking PWID about their utilization may conjure very different images across our study population. Further research should be undertaken to understand how rural communities, particularly first responders and public health officials, would envision a SCS operating in their community and how this vision marries that of PWID. Second, injection drug use is highly stigmatized, especially in rural communities. As such, it is possible that some PWID did not take the survey in order to avoid stigmatization. Last, social desirability bias may have impacted how participants answered survey questions. We attempted to mitigate this bias by administering the survey via ACASI and collecting data anonymously. Despite these limitations, the study did reach a very diverse group of rural PWID and provides valuable insights into the characteristics of the population who likely would use a SCS.
Acceptability of hypothetical SCS use was very high among our rural population of PWID in WV. Our findings suggest that rural PWID most likely to use a hypothetical SCS also engage in high-risk injection drug use practices. Given that SCS implementation remains a hypothetical scenario in a US context, future research should qualitatively explore factors associated with SCS acceptability among rural PWID. SCS may be a viable option to reduce overdose fatalities in rural communities.
Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to concerns about confidentiality.
human immunodeficiency virus
injection drug use
people who inject drugs
safe consumption spaces
United States of America
Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths – United States, 2013-2017. Morb Mortal Wkly Rep. ePub: 2018.
Nash, B. Herald Dispatch. Cabell led state in overdose deaths in 2017; non-fatal pace slowing. (2018).https://www.herald-dispatch.com/news/cabell-led-state-in-overdose-deaths-in-non-fatal-pace/article_e6085520-c817-5bce-a793-c1bcdabe844b.html. Accessed on 7 Mar 2019.
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010. https://doi.org/10.1016/S0140-6736(10)60743-X.
Vlahov D, Fuller C, Ompad D, Galea S, Des JD. Updating the infection risk reduction hierarchy: preventing transition into injection. J Urban Health. 2004;81(1):14–9.
Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco. Calif. Am J Public Health. 2001;91(1):46–7.
Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008;8:405.
Gonsalves GS, Crawford FW. Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011–15: a modelling study. The Lancet HIV. 2018. https://doi.org/10.1016/S2352-3018(18)30176-0.
Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016. https://doi.org/10.1097/QAI.0000000000001098.
Doherty MC, Garfein RS, Vlahov D, Junge B, Rathouz PJ, Galai N, et al. Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol. 1997;145(8):730–7.
Doherty MC, Junge B, Rathouz P, Garfein RS, Riley E, Vlahov D. The effect of a needle exchange program on numbers of discarded needles: a 2-year follow-up. Am J Public Health. 2000;90(6):936–9.
Broadhead RS, van Hulst Y, Heckathorn DD. The impact of a needle exchange’s closure. Public Health Rep. 1999;114(5):439–47.
Oliver KJ, Friedman SR, Maynard H, Magnuson L, Des Jarlais DC. Impact of a needle exchange program on potentially infectious syringes in public places. J Acquir Immune Defic Syndr. 1992;5(5):534–5.
Dovey K, Fitzgerald J, Choi Y. Safety becomes danger: dilemmas of drug-use in public space. Health Place. 2001;7(4):319–31.
Sutter A, Curtis M, Frost T. Public drug use in eight U.S. cities: Health risks and other factors associated with place of drug use. Int J Drug Policy. 2018. https://doi.org/10.1016/j.drugpo.2018.11.007.
Barry CL, Sherman SG, Stone E, et al. Arguments supporting and opposing legalization of safe consumption sites in the U.S. Int J Drug Policy. 2019. https://doi.org/10.1016/j.drugpo.2018.10.008.
Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ. 2006. https://doi.org/10.1503/cmaj.060863.
van Beek I, Dakin A, Kimber J, Gilmour S. The Sydney medically supervised injecting centre: reducing harm associated with heroin overdose. Critical public health. 2004;14:391–406.
Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America’s first medically-supervised safer injection facility. PLoS ONE. 2008. https://doi.org/10.1371/journal.pone.0003351.
Potier C, Laprévote V, Dubois-arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014. https://doi.org/10.1016/j.drugalcdep.2014.10.012.
Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004. https://doi.org/10.1503/cmaj.1040774.
Debeck K, Kerr T, Bird L, et al. Injection drug use cessation and use of North America’s first medically supervised safer injecting facility. Drug Alcohol Depend. 2011. https://doi.org/10.1016/j.drugalcdep.2010.07.023.
Gaddis A, Kennedy MC, Nosova E, et al. Use of on-site detoxification services co-located with a supervised injection facility. J Subst Abuse Treat. 2017. https://doi.org/10.1016/j.jsat.2017.08.003.
Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E. Attendance, drug use patterns, and referrals made from North America’s first supervised injection facility. Drug Alcohol Depend. 2006. https://doi.org/10.1016/j.drugalcdep.2005.11.011.
Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007. https://doi.org/10.1111/j.1360-0443.2007.01818.x.
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011. https://doi.org/10.1016/S0140-6736(10)62353-7.
Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm Reduct J. 2017. https://doi.org/10.1186/s12954-017-0153-2.
Jozaghi E, Reid AA, Andresen MA. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. Subst Abuse Treat Prev Policy. 2013. https://doi.org/10.1186/1747-597X-8-25.
Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13.
Freeman K, Jones CG, Weatherburn DJ, Rutter S, Spooner CJ, Donnelly N. The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug Alcohol Rev. 2005;24(2):173–84.
Salmon AM, Van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction. 2010. https://doi.org/10.1111/j.1360-0443.2009.02837.x.
Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia. Int J Drug Policy. 2018. https://doi.org/10.1016/j.drugpo.2017.11.005.
Kral AH, Wenger L, Carpenter L, Wood E, Kerr T, Bourgois P. Acceptability of a safer injection facility among injection drug users in San Francisco. Drug Alcohol Depend. 2010. https://doi.org/10.1016/j.drugalcdep.2010.02.009.
Bouvier BA, Elston B, Hadland SE, Green TC, Marshall BD. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study. Harm Reduct J. 2017. https://doi.org/10.1186/s12954-017-0139-0.
Park JN, Rouhani S, Morales K, Green TC, McKenzie M, Marshall BDL, Sherman SG. Willingness to use safer consumption spaces among opioid users at high risk of fentanyl overdose in Baltimore, Providence, and Boston. J Urban Health. 2019. https://doi.org/10.1007/s11524-019-00365-1.
Allen ST, O’Rourke A, White RH, Schneider KE, Kilkenny M, Sherman SG. Estimating the number of people who inject drugs in a rural county in Appalachia. Am J Public Health. 2019. https://doi.org/10.2105/AJPH.2018.304873.
Allen ST, O’Rourke A, White RH, Schneider KE, Hazelett T, Kilkenny M, Sherman SG. 2019. Applying population estimation methods in rural America. Retrieved from https://americanhealth.jhu.edu/themes/bahi_stable/assets/pdfs/Opioid_Services_Toolkit_012419.pdf. Accessed on 27 June 2019.
Allen ST, O’Rourke A., White RH, Schneider KE, Hazelett T, Kilkenny M, Sherman SG. 2019. Rural communities in crisis. Retrieved from. https://americanhealth.jhu.edu/RuralOpioidsCount. Accessed on 27 June 2019.
Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, Sherman SG. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16(1):33. https://doi.org/10.1186/s12954-019-0305-7.
Debeck K, Kerr T, Lai C, Buxton J, Montaner J, Wood E. The validity of reporting willingness to use a supervised injecting facility on subsequent program use among people who use injection drugs. Am J Drug Alcohol Abuse. 2012. https://doi.org/10.3109/00952990.2011.600389.
Praderio, C. Insider. A fire chief in West Virginia helped change her city’s approach to the opioid epidemic. Now overdoses in her county are down 40% (2019). https://www.thisisinsider.com/west-virginia-fire-chief-jan-rader-opioid-epidemic-ted-talk-2018-12. Accessed on 6 Feb 2019.
This research was supported by a grant from the Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health to Dr. Sean T. Allen. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), and DC Center for AIDS Research (AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. STA is also supported by the National Institutes of Health (K01DA046234). The funders had no role in study design, data collection, or in analysis and interpretation of the results, and this paper does not necessarily reflect views or opinions of the funders. We are grateful for the collaboration of the Cabell-Huntington Health Department, without whom, this project would not have been possible. Most importantly, we are grateful to our study participants.
This study was supported by a grant from the Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health to Dr. Sean T. Allen. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189), and DC Center for AIDS Research (AI117970), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. STA is also supported by the National Institutes of Health (K01DA046234).
Ethics approval and consent to participate
All participants were verbally consented. This study was approved by the Johns Hopkins Institutional Review Board.
Consent for publication
The authors have no competing interests to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.